- Home
- ALGS vs MRNS Comparison
ALGS vs MRNS Comparison
Compare ALGS & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALGS
- MRNS
- Stock Information
- Founded
- ALGS 2018
- MRNS 2003
- Country
- ALGS United States
- MRNS United States
- Employees
- ALGS N/A
- MRNS N/A
- Industry
- ALGS Biotechnology: Pharmaceutical Preparations
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- ALGS Health Care
- MRNS Health Care
- Exchange
- ALGS Nasdaq
- MRNS Nasdaq
- Market Cap
- ALGS 23.5M
- MRNS 19.0M
- IPO Year
- ALGS 2020
- MRNS 2014
- Fundamental
- Price
- ALGS $19.17
- MRNS $0.30
- Analyst Decision
- ALGS Strong Buy
- MRNS Buy
- Analyst Count
- ALGS 1
- MRNS 12
- Target Price
- ALGS $75.00
- MRNS $4.28
- AVG Volume (30 Days)
- ALGS 476.7K
- MRNS 6.6M
- Earning Date
- ALGS 11-06-2024
- MRNS 11-12-2024
- Dividend Yield
- ALGS N/A
- MRNS N/A
- EPS Growth
- ALGS N/A
- MRNS N/A
- EPS
- ALGS N/A
- MRNS N/A
- Revenue
- ALGS $5,997,000.00
- MRNS $31,466,000.00
- Revenue This Year
- ALGS N/A
- MRNS $20.74
- Revenue Next Year
- ALGS N/A
- MRNS $32.38
- P/E Ratio
- ALGS N/A
- MRNS N/A
- Revenue Growth
- ALGS N/A
- MRNS 1.63
- 52 Week Low
- ALGS $6.76
- MRNS $0.26
- 52 Week High
- ALGS $30.00
- MRNS $11.26
- Technical
- Relative Strength Index (RSI)
- ALGS 82.79
- MRNS 25.07
- Support Level
- ALGS $15.66
- MRNS $0.29
- Resistance Level
- ALGS $21.89
- MRNS $0.37
- Average True Range (ATR)
- ALGS 2.25
- MRNS 0.04
- MACD
- ALGS 1.24
- MRNS 0.02
- Stochastic Oscillator
- ALGS 79.79
- MRNS 17.95
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.